Loading search results
Sponsor study identifier
observational
300
6 countries
6
Study Start
December 28, 2021
Actual (reported)Primary Completion
July 15, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Malignant peritoneal mesothelioma is a rare neoplasm. The most common type, the epithelioid type, has been further divided into histological patterns of tubulo-papillary, acinar, adenomatoid, micropapillary, or solid. Its prognosis is improved by the use of a locoregional treatment combining extensive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), which increases survival up to 50 months. Histology is one of the most important prognostic variable that, forms the basis for treatment decisions. However, the prognostic of the epithelioid type varies greatly due to its tumor heterogeneity. It is therefore necessary to find prognostic factors of malignant epithelioid peritoneal mesothelioma in order to better define the therapeutic strategy. Among histological factors, solid growth, tumor necrosis, nuclear atypia, and mitotic count were found to be independent prognostic factors in epithelioid malignant pleural mesothelioma. However, in epithelioid malignant peritoneal mesothelioma (EMPM), these factors were studied in small and heterogeneous series in terms of histological growth and definitions used for histological factors. The present large study was conducted to investigate the prognostic impact of several histologic factors in EMPM. Their prognosis impacts were assessed using overall survival (OS) and progression-free survival (PFS) in EMPM.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 28, 2021
Actual (reported)December 31, 2021
Actual (reported)January 14, 2022
Actual (reported)July 15, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Assessment of pronostic impact of nuclear grade in comparison with combined grade in peritoneal malignant mesothelioma
Assessment by the review of pathologists
3 months to 4 years
peritoneal malignant mesothelioma of grade 1
peritoneal malignant mesothelioma of grade 2
peritoneal malignant mesothelioma of grade 3
No intervention
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
squamous cell carcinoma of the oropharynx
UZ Gent
Ghent, 9000, Belgium
University Hospital of Lyon
Pierre-Bénite, 69495, France
First Submitted
December 31, 2021
First Posted
January 14, 2022
Study Start
December 28, 2021
Actual (reported)Primary Completion
July 15, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Contact the study team to confirm eligibility.
Institut f. Pathologie und Neuropathologie
Tübingen, 72076, Germany
Zydus Hospitals
Ahmedabad, India
The Norwegian Radium Hospital
Oslo, N-0310, Norway
Fundação Champalimaud
Lisbon, 1400-038, Portugal
Study Completion
January 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
January 14, 2022
Record last verified: 2021-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: